Dianthus Therapeutics (NASDAQ:DNTH) SVP Adam Veness Sells 16,167 Shares

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) SVP Adam Veness sold 16,167 shares of the company’s stock in a transaction that occurred on Monday, August 10th. The stock was sold at an average price of $110.38, for a total value of $1,784,513.46. Following the transaction, the senior vice president directly owned 3,833 shares in the company, valued at $423,086.54. The trade was a 80.84% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

Dianthus Therapeutics Trading Down 3.0%

Shares of DNTH stock opened at $108.49 on Wednesday. The firm has a market capitalization of $5.93 billion, a PE ratio of -26.14 and a beta of 1.22. The firm has a fifty day simple moving average of $95.71 and a two-hundred day simple moving average of $81.79. Dianthus Therapeutics, Inc. has a 12 month low of $19.00 and a 12 month high of $114.55.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.90) earnings per share for the quarter, missing the consensus estimate of ($0.85) by ($0.05). Dianthus Therapeutics had a negative return on equity of 22.53% and a negative net margin of 10,096.95%.The business had revenue of $0.76 million for the quarter, compared to analyst estimates of $0.30 million. On average, equities analysts predict that Dianthus Therapeutics, Inc. will post -3.83 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on DNTH shares. Wolfe Research reaffirmed an “outperform” rating on shares of Dianthus Therapeutics in a research report on Wednesday, June 10th. Raymond James Financial reissued a “strong-buy” rating and issued a $131.00 price objective on shares of Dianthus Therapeutics in a research note on Wednesday, August 5th. Guggenheim restated a “buy” rating on shares of Dianthus Therapeutics in a report on Wednesday, June 10th. Wall Street Zen raised Dianthus Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. Finally, Wedbush lifted their target price on Dianthus Therapeutics from $105.00 to $122.00 and gave the company an “outperform” rating in a research report on Wednesday, August 5th. One investment analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $124.27.

Dianthus Therapeutics News Roundup

Here are the key news stories impacting Dianthus Therapeutics this week:

• Positive Sentiment: HC Wainwright issued an optimistic estimate for Dianthus Therapeutics’ earnings, offering a potential bullish catalyst for DNTH. However, the report did not provide specific revised earnings targets. HC Wainwright Issues Optimistic Estimate for DNTH Earnings
• Neutral Sentiment: Reported short interest was zero shares as of August 11, unchanged from the prior reporting period, with a days-to-cover ratio of zero. This indicates little evidence of active short-selling pressure or a potential short squeeze in DNTH.
• Negative Sentiment: Several insiders sold shares around $109 to $111. Senior Vice President Adam M. Veness sold 20,000 shares across transactions on August 7 and August 10 for approximately $2.21 million, reducing his position by roughly 80.8% overall. SEC insider trading filing
• Negative Sentiment: Director Simon Read sold 2,777 shares for about $304,000, cutting his holdings by 50%. Director Anne McGeorge sold 7,750 shares for approximately $845,000, reducing her position by about 86%. The timing and size of these sales could raise concerns because they occurred while the stock was trading near its 12-month high. SEC director trading filing

Institutional Trading of Dianthus Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the business. Raymond James Financial Inc. purchased a new position in Dianthus Therapeutics in the second quarter worth $27,000. First Horizon Corp bought a new stake in shares of Dianthus Therapeutics during the 1st quarter worth $32,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Dianthus Therapeutics in the 4th quarter worth about $40,000. Russell Investments Group Ltd. bought a new position in Dianthus Therapeutics during the third quarter valued at about $64,000. Finally, Tower Research Capital LLC TRC increased its holdings in Dianthus Therapeutics by 330.7% during the second quarter. Tower Research Capital LLC TRC now owns 4,320 shares of the company’s stock worth $80,000 after buying an additional 3,317 shares during the last quarter. 47.53% of the stock is owned by hedge funds and other institutional investors.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.